Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Emmes Group partners with Miimansa AI to accelerate adoption of Generative AI in clinical research
Emmes Group, a leading specialty tech-enabled global contract research organization (CRO), today announced a multi-year strategic partnership with Miimansa AI. A critical pillar of the partnership, aimed at revolutionizing clinical research at Emmes, is the...
mRNA Vaccines and Therapeutics Market to Reach US$ 85.9 billion, Garnering a 14.6% CAGR by 2034: Transparency Market Research Inc.
Besides vaccines, mRNA technology is being explored for therapeutic applications in oncology, infectious diseases, genetic disorders, and other areas. This diversification expands the market potential. The mRNA vaccines and therapeutics market was projected to attain...
Study finds siRNA ineffective in reducing mutant huntingtin gene mRNA in nucleus
Huntingtin. Crystallographic structure of the N-terminal region of the human Huntingtin protein with an artificially attached Maltose-Binding protein used for crystallographic purposes. Credit: Public domainIn Huntington's disease, the mutant huntingtin gene (HTT)...
Agilent Technologies to acquire CDMO Biovectra for $925M
Agilent Technologies plans to buy Canadian CDMO Biovectra in a $925 million deal, which Agilent says will deepen its focus on oligonucleotides and CRISPR. Biovectra says it has fill-finish services, pDNA and mRNA capabilities, lipid nanoparticle formulation and...
Scientists develop potential stealth cancer therapy
Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...
Cancer Gene Therapy Market to Attain a USD 12.63 Billion by 2031; Advancements in Gene Technologies Augment Development
According to SkyQuest, the global Cancer Gene Therapy Market size was valued at USD 2.38 billion in 2022 and is poised to grow from USD 2.86 billion in 2023 to USD 12.63 billion by 2031, growing at a CAGR of 20.42% in the forecast period (2024-2031). Cancer has...
Tiba Biotech Partners with BARDA to Develop Groundbreaking Influenza Therapeutics
Tiba Biotech LLC, a Cambridge-based preclinical biopharmaceutical company, has announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S....
Lexeo Therapeutics Announces Promising Interim Results in Friedreich Ataxia Cardiomyopathy Trials
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical-stage genetic medicine company, has announced positive interim data from its ongoing trials for LX2006, a gene therapy treatment targeting Friedreich ataxia (FA) cardiomyopathy. The results, emerging from both the...
Popular Services
AAV Packaging Service
AAV Analytical Service
Vector Design